Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD

Schermer, Tjard; Albers, J.M.C.; Verblackt, H.W.J.; Costongs, Robert; Westers, Paul

doi:10.1093/fampra/cml076

Cited by 14 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study performed in family practice showed that the salmeterol/fluticasone combination, compared with conventional fluticasone treatment, permits to better achieve several treatment goals: FEV1 ( P = 0.025), PEF ( P = 0.016) and symptoms‐free days for week ( P = 0.044). These benefits were not perceived by patients, since, in AQLQ overall score and SGRQ scores, no differences were detected between the two treatments (22).…”

Section: Resultsmentioning

confidence: 99%

The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA²LEN review

Baiardini

Braido

Brandi

et al. 2008

Allergy

View full text Add to dashboard Cite

Asthma represents a serious global health problem. People of all ages in countries throughout the world are affected by this chronic airway disorder that, when uncontrolled, can place severe limits on daily life and can even be fatal. Asthma cannot be removed, but asthmatic symptoms can be cured; as for many other chronic diseases, pharmacotherapy is important to reduce the risk of asthma‐related mortality, decrease disability and improve symptoms and quality of life. The action of antiasthmatic drugs directly contributes to decrease symptoms severity, improve spirometric results, reduce airway hyperresponsiveness and prevent irreversible airway remodelling. Antiasthmatic therapy is necessary for long‐term control of asthma symptoms. Asthma and antiasthmatic drugs can influence patient’s quality of life: this is why healthcare systems have recently focused on research studies about Health‐Related Quality of Life (HRQL) in asthmatic patients. Numerous validated questionnaires are available and many studies have been performed evaluating HRQL in people affected by asthma, thus testifying a great interest in this topic. The aims of the present review are to examine the scientific literature of the last 4 years (January 2004–December 2007) dealing with the impact of asthma treatments suggested by Global Initiative for Asthma guidelines on patients’ quality of life, and to identify the unexplored or not fully investigated areas concerning this issue.

show abstract

Section: Resultsmentioning

confidence: 99%

The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA²LEN review

Baiardini

Braido

Brandi

et al. 2008

Allergy

View full text Add to dashboard Cite

show abstract

“…Outcome was onset of action. No LABA alone arm Schermer 2007 Only one arm with FPS Sethi 2006 Outcome was bacterial colonization for FPS Sutherland 2006 Genetic study of FPS Trofimenko 2006 FPS with no comparison Zheng 2006 FPS with no comparison …”

Section: Electronic Searches: Core Databasesmentioning

confidence: 99%

Combined corticosteroid and long-acting beta₂ -agonist in one inhaler versus long-acting beta₂ -agonists for chronic obstructive pulmonary disease

Nannini¹,

Lasserson

Poole

2012

Cochrane Database of Systematic Reviews

173

View full text Add to dashboard Cite

show abstract

Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease

Nannini¹,

Cates²,

Lasserson³

et al. 2007

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Compared with placebo, combination therapy led to a significant reduction of a quarter in exacerbation rates. There was a significant reduction in all-cause mortality with the addition of data from the TORCH trial. The increased risk of pneumonia is a concern, and better reporting of this outcome in future studies would be helpful. In order to draw firmer conclusions about the effects of combination therapy in a single inhaler more data are necessary, particularly in relation to the profile of adverse events and benefits in relation to different doses of inhaled corticosteroids.

show abstract

Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD

Abstract: In family practice patients diagnosed with asthma, several treatment goals were better achieved with a lower dose of fluticasone and salmeterol in a combination product than with a higher dose of fluticasone. We found no differences between the two approaches for patients with COPD.

Cited by 14 publications

References 19 publications

The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA²LEN review

The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA²LEN review

Combined corticosteroid and long-acting beta₂ -agonist in one inhaler versus long-acting beta₂ -agonists for chronic obstructive pulmonary disease

Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease

Contact Info

Product

Resources

About

Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD

Abstract: In family practice patients diagnosed with asthma, several treatment goals were better achieved with a lower dose of fluticasone and salmeterol in a combination product than with a higher dose of fluticasone. We found no differences between the two approaches for patients with COPD.

Cited by 14 publications

References 19 publications

The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA2LEN review

The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA2LEN review

Combined corticosteroid and long-acting beta2 -agonist in one inhaler versus long-acting beta2 -agonists for chronic obstructive pulmonary disease

Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease

Contact Info

Product

Resources

About

The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA²LEN review

The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA²LEN review

Combined corticosteroid and long-acting beta₂ -agonist in one inhaler versus long-acting beta₂ -agonists for chronic obstructive pulmonary disease